JP2017532005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532005A5 JP2017532005A5 JP2017508053A JP2017508053A JP2017532005A5 JP 2017532005 A5 JP2017532005 A5 JP 2017532005A5 JP 2017508053 A JP2017508053 A JP 2017508053A JP 2017508053 A JP2017508053 A JP 2017508053A JP 2017532005 A5 JP2017532005 A5 JP 2017532005A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- amino
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 518
- 150000001413 amino acids Chemical class 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 28
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 13
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000009830 antibody antigen interaction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 102000054439 human MMP9 Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180765.1 | 2014-08-13 | ||
| EP14180765.1A EP2985296A1 (en) | 2014-08-13 | 2014-08-13 | Antibodies specific for MMP9 |
| PCT/EP2015/068645 WO2016023979A1 (en) | 2014-08-13 | 2015-08-13 | Antibodies specific for mmp9 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532005A JP2017532005A (ja) | 2017-11-02 |
| JP2017532005A5 true JP2017532005A5 (enExample) | 2018-09-20 |
| JP6856523B2 JP6856523B2 (ja) | 2021-04-07 |
Family
ID=51301193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508053A Active JP6856523B2 (ja) | 2014-08-13 | 2015-08-13 | Ｍｍｐ９特異的な抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10364296B2 (enExample) |
| EP (2) | EP2985296A1 (enExample) |
| JP (1) | JP6856523B2 (enExample) |
| KR (1) | KR20170041222A (enExample) |
| CN (1) | CN106573984A (enExample) |
| AU (1) | AU2015303183B2 (enExample) |
| BR (1) | BR112017002703A2 (enExample) |
| CA (1) | CA2956986A1 (enExample) |
| ES (1) | ES2784271T3 (enExample) |
| MX (1) | MX380238B (enExample) |
| PL (1) | PL3180362T3 (enExample) |
| RU (1) | RU2714043C2 (enExample) |
| WO (1) | WO2016023979A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3440113A1 (en) | 2016-04-08 | 2019-02-13 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| CN110312737A (zh) | 2016-12-16 | 2019-10-08 | 波尔多大学 | Mmp9抑制剂及其在预防或治疗色素脱失病症中的用途 |
| AU2018278275B2 (en) | 2017-06-02 | 2025-06-05 | Ablynx N.V. | MMP13 binding immunoglobulins |
| WO2019004430A1 (ja) * | 2017-06-30 | 2019-01-03 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 大腸がんを検出するためのバイオマーカー |
| US11926655B2 (en) | 2017-07-18 | 2024-03-12 | Daiichi Sankyo Company, Limited | Active MMP9-binding peptide |
| JP2021506763A (ja) | 2017-12-13 | 2021-02-22 | ノース カロライナ ステート ユニバーシティＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ | 化学療法剤とチェックポイント阻害剤とを含む組成物及び使用の方法 |
| JP7297770B2 (ja) * | 2018-01-22 | 2023-06-26 | リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー | 結腸がんの検出および治療の方法 |
| CN108277214B (zh) * | 2018-02-23 | 2021-07-06 | 广东医科大学 | 一种应激磷酸化抗原多肽、抗体、制备方法以及应用 |
| WO2020237092A2 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Mmp-9 antibodies and methods of use thereof |
| CN110885375B (zh) * | 2019-12-20 | 2021-07-02 | 南京融捷康生物科技有限公司 | 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用 |
| WO2023278491A1 (en) * | 2021-06-28 | 2023-01-05 | Releviate, Llc | Mmp-9 antibodies and uses thereof |
| JP2023021745A (ja) * | 2021-08-02 | 2023-02-14 | 学校法人東京薬科大学 | がん転移抑制のための医薬組成物 |
| CN117327186B (zh) * | 2023-07-12 | 2024-03-12 | 北京达成生物科技有限公司 | 结合mmp3蛋白的双特异性抗体及其用途 |
| WO2025076280A1 (en) | 2023-10-05 | 2025-04-10 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
| CN117264069B (zh) * | 2023-11-23 | 2024-01-26 | 再少年(北京)生物科技有限公司 | 一种促进皮肤组织再生的工程化外泌体的制备方法及其应用 |
| CN117820488B (zh) * | 2024-01-09 | 2024-10-01 | 首都医科大学附属北京朝阳医院 | 特异性针对mmp-9的抗体对、生物材料及其应用 |
| CN117964771B (zh) * | 2024-04-02 | 2024-06-21 | 智泽童康(广州)生物科技有限公司 | 一种特异性结合mmp7的抗体、mmp7检测试剂及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002235692A1 (en) * | 2001-02-23 | 2002-09-04 | Biophage Inc. | Methods and compositions for preventing and treating neutrophil-mediated diseases |
| GB0516069D0 (en) | 2005-08-04 | 2005-09-14 | Imp College Innovations Ltd | Pharmaceutical and use thereof |
| MX2009008914A (es) * | 2007-02-23 | 2009-08-28 | Yeda Res & Dev | Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. |
| WO2009111508A2 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| AU2009222048A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 binding proteins |
| WO2010045388A2 (en) * | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis |
| US20110135573A1 (en) | 2009-09-03 | 2011-06-09 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| AP2016009448A0 (en) * | 2010-08-27 | 2016-09-30 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
| HK1208036A1 (en) | 2012-02-29 | 2016-02-19 | 吉联亚生物科技有限公司 | Antibodies to matrix metalloproteinase 9 |
| HK1204981A1 (en) * | 2012-02-29 | 2015-12-11 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
-
2014
- 2014-08-13 EP EP14180765.1A patent/EP2985296A1/en not_active Withdrawn
-
2015
- 2015-08-13 US US15/503,447 patent/US10364296B2/en not_active Expired - Fee Related
- 2015-08-13 AU AU2015303183A patent/AU2015303183B2/en not_active Ceased
- 2015-08-13 EP EP15749818.9A patent/EP3180362B1/en active Active
- 2015-08-13 KR KR1020177004988A patent/KR20170041222A/ko not_active Ceased
- 2015-08-13 CA CA2956986A patent/CA2956986A1/en not_active Abandoned
- 2015-08-13 RU RU2017107773A patent/RU2714043C2/ru active
- 2015-08-13 CN CN201580043394.1A patent/CN106573984A/zh active Pending
- 2015-08-13 BR BR112017002703-8A patent/BR112017002703A2/pt not_active IP Right Cessation
- 2015-08-13 MX MX2017001959A patent/MX380238B/es unknown
- 2015-08-13 ES ES15749818T patent/ES2784271T3/es active Active
- 2015-08-13 JP JP2017508053A patent/JP6856523B2/ja active Active
- 2015-08-13 WO PCT/EP2015/068645 patent/WO2016023979A1/en not_active Ceased
- 2015-08-13 PL PL15749818T patent/PL3180362T3/pl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532005A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| CN104903350B (zh) | 特异于clec14a的新抗体及其用途 | |
| JP2020522261A5 (enExample) | ||
| RU2012137515A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| JP2010526028A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| RU2013153592A (ru) | Анти-mif антитела | |
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| JP2014524733A5 (enExample) | ||
| JP2017534259A5 (enExample) | ||
| JP2019520034A5 (enExample) | ||
| RU2016135962A (ru) | Выделенное антитело, способ его получения, выделенная нуклеиновая кислота, экспрессионная кассета, клетка-хозяин, фармацевтический и диагностический препараты, способ лечения больного, подверженного риску или страдающего от инфекции E.COLI, и способ диагностики определения инфекций E.COLI | |
| JP2023153982A (ja) | 抗プレキシンａ１アゴニスト抗体 | |
| JP2018528759A5 (enExample) | ||
| RU2016106708A (ru) | Лекарственное средство, содержащее антитело к фосфолипазе d4 | |
| JP2019500855A (ja) | ヒト化抗−ｂａｇ３抗体 | |
| EP4486782A1 (en) | Anti-rage antibody | |
| KR20250152073A (ko) | 항체, 항원 결합 단편 및 사용 방법 | |
| WO2021225954A1 (en) | Inhibiting anti-enpp1 antibodies | |
| CN118562006A (zh) | 人表皮生长因子受体结合分子及其应用 | |
| KR20220054600A (ko) | Il-38-특이적 항체 | |
| TWI869740B (zh) | 一種體外檢測ｓＴＮＦＲ２蛋白濃度的方法及其檢測試劑和檢測試劑盒 | |
| CN118745226A (zh) | 抗ror1抗体及其应用 | |
| JP7762311B2 (ja) | 抗成長分化因子１５の抗体分子及びその応用 |